Loading stock…

Zydus Lifesciences Limited (ZYDUSLIFE) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Zydus Lifesciences Limited

ZYDUSLIFEMarket cap $12BPrice $12.0

Country🇮🇳India

SectorHealthcare

IndustryPharmaceuticals

Manufactures generic drugs, active pharmaceutical ingredients, and vaccines sold across 50+ countries. One of India's largest pharma players, it's also among the few globally to develop its own homegrown COVID-19 vaccine, ZyCoV-D.

In Bastion Portfolios?

52W Return+7%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+11%7

Revenue Forecast

Rev CAGR (1y)+13%7

Rev CAGR (3y)+11%7

Rev CAGR (5y)+7%6

Earnings Forecast

EPS Growth Y+1-20%2

EPS Growth Y+2+20%8

EPS Growth Y+3+5%5

Quality

Margins

EBIT Margin19%7

Net Income Margin16%7

Free Cash Flow Margin-4%2

Debt

Net Debt/EBITDA1.16

Efficiency

ROE18%7

ROAna–

Earnings Stability44

GEAR+AVERAGE55

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)273

P/E Ratio (Forward 3y)222

P/BV4.24

EV Multiples

EV/EBITDA Fwd163

EV/EBIT Fwd233

Yield

Free Cash Flow Yield-1.1%2

Dividend Yield0.1%1

Momentum

Short term

1 month return-0%8

3 month return+0%6

YTD return+26%8

Mid term

Price vs 52wHigh94%9

1 year return+17%7

Long term

3 year return+94%7

5 year return+116%8

Risk Shield

Price Risk

Beta0.39

Volatility23%9

Free Cash Flow

Free Cash Flow Margin-4%2

Free Cash Flow Yield-1.1%2

Quality

ROCE29%10

Earnings Stability44

Net Debt/EBITDA1.16

02Growth

Is it actually growing, and how fast?

ZYDUSLIFEZydus Lifesciences

Revenue FY26$2.9B

GROWTH RATING↗

AVERAGE62 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+11%7

Revenue, next 1Y+13%7

Revenue, next 3Y, CAGR+11%7

Revenue, next 5Y, CAGR+7%6

EARNINGS FORECAST▾SCORE

EPS growth, FY27E-20%2

EPS growth, FY28E+20%8

EPS growth, FY29E+5%5

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 11%/yr over the last 3 years, ahead of 60% of companies worldwide.7/10

Revenue is set to grow 11%/yr over the next 3 years, ahead of most of the market.7/10

Revenue grew 11%/yr over the last 3 years and is set to keep growing around 11%/yr.

WATCH

A mid-pack grower, ahead of 62% of companies worldwide.

Over five years revenue is set to grow 7%/yr, ahead of 50% of companies worldwide.6/10

Earnings are set to grow slower than sales (EPS about 5%/yr vs revenue 11%/yr), so margins are under pressure. One year dips: EPS falls 20% next year.

WEAKNESSES

None flagged.

BOTTOM LINE

Steady Grower

A middle-of-the-pack grower. The one thing to watch: earnings are set to grow slower than sales.

03Price Momentum

Is the market behind it right now?

ZYDUSLIFEZydus Lifesciences

Total return Current93.0%

Price return Current76.7%

MOMENTUM RATING↗

STRONG80 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-0%8

3-month return+0%6

YTD return+26%8

MID & LONG-TERM▾SCORE

% of 52-week high94%9

1-year return+17%7

3-year return+94%7

5-year return+116%8

MOMENTUM ASSESSMENT

STRENGTHS

Strong long-term results. Long-term holders have seen +94% over three years and +116% over five, ahead of 70% of the market.

It's up 17% over the past year, now 6% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+0%) and so far this year (+26%).

WATCH

Returns sit at the market level over three months (+0%).

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally, and the stock trades near its highs. The market is fully behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on Zydus Lifesciences Limited. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

ZYDUSLIFEZydus Lifesciences

Revenue FY26$2.9B

GROWTH RATING↗

AVERAGE62 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+11%7

Revenue, next 1Y+13%7

Revenue, next 3Y, CAGR+11%7

Revenue, next 5Y, CAGR+7%6

EARNINGS FORECAST▾SCORE

EPS growth, FY27E-20%2

EPS growth, FY28E+20%8

EPS growth, FY29E+5%5

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 11%/yr over the last 3 years, ahead of 60% of companies worldwide.7/10

Revenue is set to grow 11%/yr over the next 3 years, ahead of most of the market.7/10

Revenue grew 11%/yr over the last 3 years and is set to keep growing around 11%/yr.

WATCH

A mid-pack grower, ahead of 62% of companies worldwide.

Over five years revenue is set to grow 7%/yr, ahead of 50% of companies worldwide.6/10

Earnings are set to grow slower than sales (EPS about 5%/yr vs revenue 11%/yr), so margins are under pressure. One year dips: EPS falls 20% next year.

WEAKNESSES

None flagged.

BOTTOM LINE

Steady Grower

A middle-of-the-pack grower. The one thing to watch: earnings are set to grow slower than sales.

03Price Momentum

Is the market behind it right now?

ZYDUSLIFEZydus Lifesciences

Total return Current93.0%

Price return Current76.7%

MOMENTUM RATING↗

STRONG80 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-0%8

3-month return+0%6

YTD return+26%8

MID & LONG-TERM▾SCORE

% of 52-week high94%9

1-year return+17%7

3-year return+94%7

5-year return+116%8

MOMENTUM ASSESSMENT

STRENGTHS

Strong long-term results. Long-term holders have seen +94% over three years and +116% over five, ahead of 70% of the market.

It's up 17% over the past year, now 6% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+0%) and so far this year (+26%).

WATCH

Returns sit at the market level over three months (+0%).

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally, and the stock trades near its highs. The market is fully behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on Zydus Lifesciences Limited. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community